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Abstract Circulatory cell-free DNA (cf-DNA) is increased
in a variety of clinical pathologic conditions; therefore,
these markers could be widely used as markers for
detecting and monitoring several disorders. To better
understand the biology of this molecule, we analysed the
relationship between the level of circulatory cf-DNA and
physiological parameters such as gender, age and frequency
of blood donations. Paired plasma and serum samples were
obtained from 87 blood donors and 50 healthy adults who
had never donated blood. Cf-DNA was extracted from
plasma and serum samples using the MagNA Pure LC
Instrument. Quantity determination of circulatory cf-DNA
was performed by TaqMan real-time PCR for the ubiqui-
tous GAPDH gene. Our data showed that the concentration
of cf-DNA in serum was about eightfold higher than that in
plasma. Regarding the level of these circulatory species, no
significant differences were observed between the age-
matched men and women and gender-matched, different-
age cohorts, except in women who were older than 60 years
of age. Frequent blood donations did not increase the
circulatory species. Circulatory cf-DNA in plasma and
serum samples is not correlated with human gender and
human age except in women who are older than 60 years of
age. Frequent blood donation did not affect the quantity of
circulatory cf-DNA. The explanation for the latter most
likely is the short half-life time of free fetal DNA in
maternal circulation.
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Introduction
High concentrations of cell-free DNA (cf-DNA) in plas-
ma and serum samples have been widely described in a
variety of clinical pathologic conditions, such as malig-
nancies, trauma, infections, pregnancy-associated disor-
ders and autoimmune diseases [1–5]. Therefore, circulatory
cf-DNA as a biological marker has been used recently more
for the investigation of the biological nature of disease and
for clinical diagnostic applications, especially in two major
areas: cancer management and prenatal diagnosis [6–10].
In cancer patients, the levels of circulatory DNA correlated
with tumour metastasis, tumour response to therapy and
tumour recurrence. Tumour-derived circulatory nucleic
acids in the plasma or serum of cancer patients have been
introduced as a non-invasive tool for detection and sur-
veillance of several cancers [1, 2, 6, 7]. Cell-free fetal
DNA in the maternal circulation has been used for detecting
and monitoring certain fetal diseases and pathological
pregnancies, such as fetal–maternal haemorrhage, pre-
eclampsia and preterm labour and fetal chromosomal
aberrations [11–14]. Recently, it was shown that DNA
fragments released from programmed cell death or acute
cellular injury are the main sources for circulatory cf-DNA
in a variety of clinical pathologic conditions [15–18].
However, the cellular or tissue origin of circulatory cf-DNA
existing in normal healthy individuals is unclear. We
detected cf-DNA in plasma and serum samples of healthy
individuals and healthy blood donors from the Blood
Bank, University of Basel, and analysed the correlation
between levels of circulatory cf-DNA and age, gender or
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frequency of blood donations to determine whether any
quantitative changes of circulatory cf-DNA are associated
with physiological parameters.
Materials and methods
Sample collection
Paired plasma and serum samples were obtained from 50
healthy adults by clinical detection at University Women’s
Hospital and Felix Platter Hospital of Basel and from 87
healthy blood donors. The study was approved by the
institutional review board of the University of Basel.
Informed consent was obtained from the individuals in this
study.
Processing of blood samples
The 10 ml of peripheral blood samples for coagulant serum
and 10 ml of peripheral blood samples for EDTA plasma
were taken from healthy individuals and blood donors. The
blood samples were processed immediately by centrifuga-
tion at 1,600 g for 10 min. The plasma and serum layers
were transferred to new Eppendorf tubes and centrifuged
again at maximum speed (16,000 g) for 10 min.
DNA extraction
Circulatory cf-DNAwas extracted from each 400-μl plasma
and serum sample using the MagNA Pure LC DNA
Isolation Kit—Large Volume (Roche Applied Science,
Mannheim, Germany) and the MagNA Pure LC Instrument
according to the manufacturer’s protocol. The DNA
preparations were eluted in 100 μl elution buffer according
to MagNA Pure LC software.
Quantitative analysis of cf-DNA in plasma and serum
samples
Five microliters of DNA was used as template for the
TaqMan real-time PCR analysis. The TaqMan PCR con-
ditions were standardised in our lab and have been described
previously in our various publications [9, 10, 12–14]. The
circulatory cf-DNA equivalents were calculated according
to very reproducible standard dilution curves using a
known concentration of human genomic DNA. The con-
centrations of circulatory cf-DNA were expressed as
genomic equivalents per milliliter plasma or serum.
Statistical analysis
Data were analysed with SPSS software (Statistical
Software Package for Windows). Mann–Whitney U test
and Kruskal–Wallis H were used to compare the levels of
Fig. 1 Correlation of circulato-
ry cf-DNA levels with age and
gender. Box plot indicating cf-
DNA levels [y axis, genomic
equivalents (GE)/ml] in the
study groups categorised by
gender and age (x axis, f female,
m male, p plasma, s serum, 20
age 20–40, 41 age 41–61, 61
age ≥61). The medians are indi-
cated by a line inside each box,
the 75th and 25th percentiles by
the box limits; the upper and
lower error bars represent the
10th and 90th percentiles, re-
spectively. The plasma cf-DNA
in the study group of f61p
(1978GE/ml, N=8) is higher
than that in the study groups of
f20p (943GE/ml, N=26,
p=0.008) and f41p (1126GE/ml,
N=24, p=0.018)
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circulatory cf-DNA in different groups categorised by
gender, age and frequency of blood donations.
Results
Levels of circulatory cf-DNA in plasma and serum samples
Because the plasma and serum samples were paired,
collected and prepared simultaneously, a mean concentra-
tion of 1,121.5 copies/ml was detected in the plasma
samples, whereas the circulatory cf-DNA had a mean of
9,285 copies/ml in the paired serum samples. This was
about eightfold higher than the mean concentration of the
circulatory cf-DNA in plasma samples. The difference was
statistically significant (p<0.001).
Levels of circulatory cf-DNA in male/female plasma
and serum
We compared the levels of circulatory cf-DNA in 54 age-
matched female and male plasma and serum samples. The
mean concentrations of circulatory cf-DNA in female
plasma and serum samples were 1,136 and 8,854.5
copies/ml, respectively, and in male plasma and serum
samples, they were 1,117.5 and 9,259 copies/ml, respec-
tively. The levels of circulatory cf-DNA in serum samples
in both the female and male groups were 7.56 and 8.04
times higher than in the plasma samples. Regarding the
level of circulatory cf-DNA in plasma and serum samples,
no significant difference was found between women and
men.
The levels of circulatory cf-DNA and age
No significant correlation was observed between the age of
the individuals and the concentration of circulatory cf-DNA
in plasma and serum samples using the Pearson test. The
cases in this study were grouped into three different age co-
horts, namely the groups of 20–40 years of age, 41–60 years
of age and older than 60 years of age. The levels of
circulatory cf-DNA in the three different age cohorts were
determined (977, 1,119 and 1,321 copies/ml plasma,
respectively, and 8,438, 9,839 and 9,239 copies/ml serum,
respectively). The mean concentration of circulatory cf-
DNA in the plasma samples from the age cohort of women
and men older than 60 years was higher than the other two
age cohorts of women and men younger than 60 years of age
(p<0.05). Further analysis showed that the increase was
only found in the female group from the age cohort of older
than 60 years of age (p<0.05) compared to the two younger
female groups, but not in the male group (Fig. 1). No
difference was found between women and men in the same
age cohort of older than 60 years of age. In contrast to the
plasma samples, the level of circulatory cf-DNA in serum
samples was not age-associated.
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Fig. 2 The levels of circulatory
cf-DNA and frequency of dona-
tions. Box plot indicating cf-
DNA levels (y axis, genomic
equivalents/ml) in the study
groups categorised by frequency
of blood donations (x axis, 0–80
frequencies of blood donations,
p plasma, s serum). The level of
serum cf-DNA in the study
group 11–50 (N=27) was sig-
nificantly lower than those in
the study groups 0 (N=25) and
11 (N=27) (Mann–Whitney test,
p=0.007, 0.016)
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The levels of circulatory cf-DNA and frequency of blood
donations
Eighty-seven healthy individuals donated blood as part of
this study at the University Blood Bank. The frequency of
their blood donations ranged from 2 to 128 times
(maximum of four times/year and 400 ml/time). We
evaluated whether the frequency of blood donations might
influence the release of cellular DNA into plasma and
serum fractions. The comparison between the concentration
of circulatory cf-DNA and the frequency of blood dona-
tions is summarised in Fig. 2. The concentration of
circulatory cf-DNA in the serum samples of the blood
donors who have donated blood between 11 and 50 times
was statistically significantly lower than in the individuals
who had never previously donated blood or had donated
blood fewer than 11 times (Mann–Whitney test, p<0.05).
No significant differences were observed in the other
groups.
Discussion
In our work, circulatory cf-DNA was determined by real-
time PCR with a mean concentration of 1,121.5 copy
numbers/ml in plasma samples and 9,285 copy numbers/ml
in serum samples. Similar results that serum samples have a
higher concentration of cf-DNA have been reported earlier
[19]. The release of DNA during blood clotting, causing
higher levels of DNA molecules in serum samples, has
been confirmed by several studies [18, 19]. Therefore, this
phenomenon might provide an opportunity in the future to
examine the fragility of haematopoitic cells.
Regarding the origin of circulatory cf-DNA, Liu et al.
had investigated the contribution of haematopoietic and
non-haematopoietic cells to these molecules using a gender-
mismatched bone marrow transplantation model (female
patients receiving bone marrow from male donors and male
patients receiving from female donors) [18]. The study
confirmed that haematopoietic cells are the main sources of
plasma cf-DNA. However, the distributing of lineages of
haematopoietic cells contributing to the release of cf-DNA
in the circulation remains unclear. Because total RBC
counts are known to be greater in men, we examined
whether the concentration of circulatory cf-DNA might also
be gender-related. In our study, no significant differences
concerning circulatory levels of cf-DNA between the
female and male groups were found, implying that
gender-associated differences of total RBC counts and
other physiological conditions did not influence the release
of DNA in circulation.
Age-related differences regarding physiological status
and pathological conditions are well-known. To determine
whether the age might be associated with the level of
circulating cf-DNA, we compared the age of the individuals
with the mean concentration of cf-DNA in plasma and
serum samples. No significant correlation existed between
age and copy number of cf-DNA (Pearson test). The cases
in this study were grouped into three different age cohorts
of 20–40 years, 41–60 years and older than 60 years. Only
the female individuals in the oldest group (menopause) had
significantly higher circulating cf-DNA in their plasma than
the two younger groups. No significant difference was
found between the men and the women in the same group
of over 60 years of age. The slight increased plasma cf-
DNA in the women of over 60 may be a statistical artefact
because of the limited sample sets.
In our study, individuals who donated blood frequently
compared to the individuals who had never previously
donated blood, namely, the donors who donated blood
between 11 and 50 times compared to those who donated
fewer than 11 times, had significantly lower circulatory
levels of cf-DNA in serum samples, but not in plasma
samples. As we mentioned above, if the release of the cf-
DNA reflects the fragility of haematopoietic cells, our
results could suggest that frequent blood donations may
decrease the fragility of haematopoietic cells and reduce the
release of DNA from blood clotting in serum samples.
Usually, the donors are allowed to repeat giving blood once
every 56 days (five times per year). In our study, one donor
donated blood 128 times. Our data show that highly
frequent blood donations (>80 times) did not cause any
differences in circulating cf-DNA in plasma and serum
compared to the other healthy individuals.
In conclusion, circulatory cf-DNA in plasma and serum
samples is not associated with gender and age. Overall,
frequent blood donations did not appear to affect the levels
of circulating cf-DNA. This most likely is due to the short
half-life time of free fetal DNA in maternal circulation. Any
association between the development of blood donation-
linked complications and the levels of circulating cf-DNA
can be further investigated.
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